A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA < 50 copies/mL at Week 48.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
San Francisco, California 94118, United States
Washington D.C., District of Columbia 20037, United States
Tampa, Florida 33602, United States
Manhasset, New York 11030, United States
Annandale, Virginia 22003, United States
Rio de Janeiro, 21040-360, Brazil
São Paulo, 04121-000, Brazil
Winnipeg, Manitoba R3A 1R9, Canada
Bangkok, 10330, Thailand
Bangkok, 10700, Thailand
Chiang Mai, 50200, Thailand